Drug intelligence / Profile preview

GNTI-932

Development stage: Preclinical
Lead developer: GentiBio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GNTI-932 is a preclinical autologous engineered regulatory T cell (Treg) therapy being developed by GentiBio for the treatment of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The therapy utilizes GentiBio's proprietary platform to create gut-specific CAR-engineered Tregs designed to restore immune tolerance and modulate inflammatory responses in the gastrointestinal tract. Key features of the platform include modifications to enhance Treg stability, ensure tissue-specific homing, and provide constitutive or inducible IL-2 signaling support to maintain Treg function in the inflammatory microenvironment.

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on GNTI-932.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNTI-932.

Explore the full profile